Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation

BACKGROUND In a recent randomized, placebo‐controlled trial, consolidation treatment with brentuximab vedotin (BV) decreased the risk of Hodgkin lymphoma (HL) progression after autologous stem cell transplantation (ASCT). However, the impact of BV consolidation on overall survival, quality of life,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2017-10, Vol.123 (19), p.3763-3771
Main Authors: Hui, Lucy, von Keudell, Gottfried, Wang, Rong, Zeidan, Amer M., Gore, Steven D., Ma, Xiaomei, Davidoff, Amy J., Huntington, Scott F.
Format: Article
Language:English
Subjects:
Adult
Autografts
autologous stem cell transplantation
Brentuximab Vedotin
brentuximab vedotin consolidation
Cancer
Consolidation
Consolidation Chemotherapy - economics
Consolidation Chemotherapy - methods
consolidation therapy
Construction costs
Cost analysis
Cost-Benefit Analysis
cost‐effectiveness analysis
Decision analysis
Disease Progression
Health care
Health Care Costs
Hematopoietic Stem Cell Transplantation
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Hodgkin Disease - surgery
Hodgkin lymphoma
Hodgkin's lymphoma
Humans
Immunoconjugates - therapeutic use
Immunotherapy
Indication
Lymphoma
Markov Chains
Markov model
Middle Aged
Monoclonal antibodies
Oncology
Pricing
Quality of Life
Quality-Adjusted Life Years
Risk
Risk reduction
Salvage
Sensitivity analysis
Stem cell transplantation
Stem cells
Surveillance
Targeted cancer therapy
Therapy
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!